Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31115657 | 0.83 | ADORA1 (0.49) | ADORA1ADORA2AGAAKMT2AKDM4E | |
| SCHEMBL11128572 | 0.78 | DCPS (0.48) | GAAKMT2ADCPSDHFRKDM4E | |
| SCHEMBL5434097 | 0.75 | DCPS (0.45) | ADORA1ADORA2AGAADCPSDHFR | |
| SCHEMBL24506810 | 0.75 | DCPS (0.41) | KMT2ADCPSDHFRKDM4EALDH1A1 | |
| SCHEMBL15841024 | 0.73 | ADK (0.51) | ADORA1ADORA2AGAAKMT2AKDM4E | |
| SCHEMBL13622758 | 0.72 | ADORA1 (0.64) | ADORA1ADORA2AGAAKMT2AKDM4E | |
| SCHEMBL3735138 | 0.72 | PTPN1 (0.70) | ADORA2ADCPSDHFR | |
| SCHEMBL25631527 | 0.71 | KMT2A (0.48) | ADORA1ADORA2AGAAKMT2AKDM4E | |
| SCHEMBL13040779 | 0.71 | NLRP3 (0.61) | ADORA1ADORA2AGAADCPSDHFR | |
| SCHEMBL11198287 | 0.67 | KMT2A (0.48) | ADORA1ADORA2AGAAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082920-A1 | NAD+-dependent DNA ligase inhibitors | Ricerca Biosciences, LLC | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082920-A1 | NAD+-dependent DNA ligase inhibitors | LIG3, LIG1, NQO1 | ADORA1 1049/4885ADORA2A 968/4885GAA 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.